Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short-term Investments (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Short-term Investments for 5 consecutive years, with $729000.0 as the latest value for Q4 2025.

  • Quarterly Short-term Investments changed N/A to $729000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $729000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $729000.0 for FY2025, N/A changed from the prior year.
  • Short-term Investments hit $729000.0 in Q4 2025 for Insight Molecular Diagnostics, roughly flat from $729000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.1 million in Q2 2021 to a low of $400000.0 in Q3 2022.
  • Historically, Short-term Investments has averaged $678230.8 across 4 years, with a median of $600000.0 in 2022.
  • Biggest five-year swings in Short-term Investments: soared 211.44% in 2021 and later plummeted 56.66% in 2022.
  • Year by year, Short-term Investments stood at $904000.0 in 2021, then crashed by 52.1% to $433000.0 in 2022, then rose by 1.85% to $441000.0 in 2023, then surged by 65.31% to $729000.0 in 2025.
  • Business Quant data shows Short-term Investments for IMDX at $729000.0 in Q4 2025, $729000.0 in Q3 2025, and $441000.0 in Q3 2023.